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Abstract
Background: Prostate Cancer (PCa) is the second most frequent neoplasia in men worldwide.
Previous reports suggest that the prevalence of PCa in Hispanic males is lower than in Africans
(including communities with African ancestry) and Caucasians, but higher than in Asians. Despite
these antecedents, there are few reports of open population screenings for PCa in Latin American
communities. This article describes the results of three consecutive screenings in the urban
population of Monterrey, Mexico.
Methods: After receiving approval from our University Hospital's Internal Review Board (IRB), the
screening was announced by radio, television, and press, and it was addressed to male subjects over
40 years old in general. Subjects who consented to participate were evaluated at the primary care
clinics of the University Health Program at UANL, in the Metropolitan area of Monterrey. Blood
samples were taken from each subject for prostate specific antigen (PSA) determination; they
underwent a digital rectal examination (DRE), and were subsequently interviewed to obtain
demographic and urologic data. Based on the PSA (>4.0 ng/ml) and DRE results, subjects were
appointed for transrectal biopsy (TRB).
Results: A total of 973 subjects were screened. Prostate biopsy was recommended to 125 men
based on PSA values and DRE results, but it was performed in only 55 of them. 15 of these biopsied
men were diagnosed with PCa, mostly with Gleason scores ≥ 7.
Conclusion: Our results reflect a low prevalence of PCa in general, but a high occurrence of high
grade lesions (Gleason ≥ 7) among patients that resulted positive for PCa. This observation
remarks the importance of the PCa screening programs in our Mexican community and the need
for strict follow-up campaigns.
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Background
According to the World Health Organization, cancer
causes 7 million deaths worldwide every year and prostate
cancer (PCa) is the second most frequent malignant neo-
plasia. PCa represents the second cause of death due to
cancer among Mexican men [1]. As life expectancy of the
general population increases in Latin American countries,
a positive correlation with the incidence of PCa is also
expected [2]. Screenings in these populations are scarce,
although studies in Hispanic populations living in the
United States report that this heterogeneous ethnic group
has medium risk of PCa when compared with other
groups. Early diagnosis of PCa can increase the likelihood
of cure, although screening asymptomatic men for PCa is
controversial due to problems with the screening test (e.g.,
sensitivity and specificity) as well as the lack of evidence
that screening affects population mortality from disease
[3-5]. To better understand the prevalence of risk factors
and biopsy prevalence of disease, we conducted a popula-
tion-based PCa screening using PSA and DRE in the met-
ropolitan area of Monterrey, Mexico. We describe the
results of three screening efforts.
Methods
This study was approved by the Ethics Committee of the
University Hospital, from the Universidad Autonoma de
Nuevo Leon and was thereafter announced by local radio,
television and printed press. Men over age 40 who lived in
the metropolitan area of Monterrey, Mexico were eligible
to participate. Subjects were screened in the primary
health centers of the University Health Program UANL
located in Monterrey, Apodaca, and Guadalupe (Monter-
rey's Metropolitan area). Subjects were informed of the
potential but unproven benefits and harms associated to
their participation in the study. No exclusion criteria were
considered for this study. From each participating subject
who granted his informed consent, a venous blood sam-
ple was obtained for PSA determination, a questionnaire
consisting of demographic and urologic data (American
Urological Association Symptom Index: AUA-SI) was
administered, and a DRE was performed by an urologist
or urology resident. If the serum PSA level was equal to or
above 4.0 ng/ml or the DRE was abnormal, a transrectal
biopsy (TRB) was recommended. Before biopsy, patients
were premedicated with 1 gr/day of ciprofloxacin for three
days and an enema (450 mg sodium citrate/45 mg lauryl
sulfoacetate). The transrectal ultrasound guided biopsies
(TRUS) of the prostate were performed under local
anesthesia with xilocaine gel using the biopsy system
ASAP™ with Channel Cut™ 18 GA needles (length 21 cm
with a cutting channel of 17 mm); at least six cylinders
were obtained from each patient, this number corre-
sponds to the sextant technique, a standard method prac-
ticed in Mexico. The prostatic tissue obtained was fixed in
3.7% neutral-buffered formalin for at least 3 hours, proc-
essed overnight and embedded in paraffin according to
the standard protocol. Two 5-μm thick sections were per-
formed, and stained with the Hematoxilin and Eosin
stain. The slides were evaluated for prostatic carcinoma by
two pathologists. All the neoplasms were graduated using
the Gleason score. Screenings were performed on July
2004, July 2005, and February 2006.
Results
A total of 973 subjects were screened in the study; 709
were entered the study in 2004, 225 in 2005, and 39 in
2006. Most of the screened subjects were from the state of
Nuevo Leon: 40% from Guadalupe followed by Monter-
rey, Apodaca and San Nicolas districts (31, 12 and 9%
respectively). Two percent of the subjects were from other
districts of Nuevo Leon and 1% from the neighbor states
of Coahuila, Tamaulipas, and Veracruz. The mean age of
participants at the time of the first screening was 61.9
(range: 40–98). Anthropometric measures indicated
76.5% of the men were overweight with a Body Mass
Index (BMI) above or equal to 25, 21% were had a normal
BMI (20–24.9) and 2.5% were underweight (BMI below
20). A total of 54% of subjects presented with mild (0–7
AUA-SI) obstructive urinary symptoms while 46% had
moderate (8–19 AUA-SI) or severe (20–35 AUA-SI)
Table 1: Age, Body Mass Index, and Urologic Data for the General Population Screened compared with data from PCa Subjects.
Attribute General Population Screened Subjects with PCa
n = 958 n = 15
Age Mean (range) 61.9 (40–98) 69.6 (55–84)
Mean BMI 27.98 26.57
Mean AUA score 8.72 10.4
Mild Urinary Symptoms (%) * 53.94 33.33
Moderate Urinary Symptoms (%)# 33.82 53.33
Severe Urinary Symptoms (%)~ 12.24 13.33
* AUA Symptom Index Score Range from 0 to 7.
# AUA Symptom Index Score Range from 8 to19.
~ AUA Symptom Index Score Range from 20 to 35.BMC Cancer 2009, 9:91 http://www.biomedcentral.com/1471-2407/9/91
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obstructive symptoms. Table 1 shows age, BMI, and uro-
logic data for the studied population, compared with the
data obtained from subjects diagnosed with PCa.
In the 2004 screening, we found 77 subjects with PSA lev-
els above 4 ng/ml; and one subject with PSA level <4, but
an abnormal DRE. Of these subjects, 41 elected to
undergo TRB. Pathological evaluation found that 13
(31.7%) of these men had cancer, 92.3% being high grade
(Gleason ≥ 7) disease. (Table 2)
During the 2005 screening effort, we detected 37 men
with PSA levels above 4 ng/ml and 11 biopsies were per-
formed; one of them (9.9%) ultimately diagnosed
Gleason 9, metastasic PCa. (Table 2)
In 2006 we found ten subjects with PSA levels above 4 ng/
ml. Three biopsies were performed and we found one sub-
ject (33.33%) with PCa, Gleason score 8. The PSA deter-
mination levels for these subjects are presented on table 2.
Overall, fifty-five core biopsies from 124 subjects with
suspicion of PCa (by PSA and DRE criteria) were submit-
ted for pathological evaluation and a total of 15 cases of
PCa were found in the screenings. The typical features of
prostatic carcinoma like a single epithelial layered gland,
huge nucleolus and conspicuous nucleoli were observed;
some of the glands showed back to back pattern of
growth, lymphatic and vascular infiltration; 14 of the car-
cinomas (93%) had Gleason scores equal or above 7. Sixty
seven percent of the subjects with PCa had moderate to
severe obstructive symptoms according to their AUA-SI
scores. None of the men with prostate cancer had a history
of PCa in their families, and only 2 had a family history of
other types of cancer (Colon Ca, and Breast Ca). Most of
the subjects with PCa (66.6%) were overweight, with a
Body Mass Index (BMI) equal or above 25. Only one of
these subjects was reported as smoker at the time of the
interview and seven (46.6%) were taking nutritional sup-
plements, mostly multivitamin compounds. Table 1
shows Age, BMI and AUA data for these subjects com-
pared with general population. 98 screened patients were
older than 75 years (10.07%). The age distribution of sub-
jects that underwent biopsy (Figure 1) shows that PCa was
diagnosed in 12/37 subjects from 40 to 74 years old
(32.43%), while this tumor was diagnosed in 3/6 subjects
older than 75 years old (50.0%).
The only histological type of PCa detected was adenocar-
cinoma (Figure 2). As for the other histological findings,
the most common was chronic prostatitis (51%), fol-
lowed by malignant neoplasia (27%), benign prostatic tis-
sue (11%), atrophy (5%), chronic prostatitis with
secondary acute prostatitis (4%), and prostatic adenoma-
tous hyperplasia (2%). Chronic prostatitis, being the most
common diagnosis, was found in association to benign
prostatic tissue in 86% of the samples, followed by 7% in
hyperplasic prostatic tissue, 5% atrophic tissue, and
finally accompanied by prostatic infarct in 2%.
Regarding the prostate biopsies performed for the study,
81.8% were due to elevated PSA, while 18.2% were exclu-
sively due to an abnormal DRE. Table 3 displays the false
positive and negative rates as well as the predictive values,
sensitivity and specificity rates of these tests according to
our results.
Discussion
Since PCa is one of the main causes of death among men
worldwide, availability of screening tests make early detec-
tion an attractive public health option for developed coun-
tries. The American Cancer Society recommends offering the
combination of PSA and DRE annually to men over age 50
and to men over age 45 for subjects with additional risk fac-
tors such as a family history of PCa or African American eth-
nicity [6]. Our series is the first report of a public screening
Table 2: PSA levels for subjects in the screenings of 2004, 2005 and 2006, cases of PCa found, and their Gleason scores.
PSA levels 
(ng/ml)






















0.1 – 4.0 620 1 7 175 0 - 29 0 -
4.1 – 8.0 53 2 7,8 22 0 - 5 0 -
8.1–12.0 10 4 7,8,6,9 6 0 - 4 1 8
> 12.0 14 6 7,9,7,9,9,8 9 1 9 1 0 -
Total 697 ￿ 13 - 212 † 1 - 39 1 -
￿ PSA could not be measured for 12 subjects due to insufficient blood sample.
† PSA could not be measured for 13 subjects due to insufficient blood sample.
* Prostate cancer cases found only within the 55 biopsies performed in these screenings.BMC Cancer 2009, 9:91 http://www.biomedcentral.com/1471-2407/9/91
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Age distribution of biopsied subjects (n = 55) Figure 1
Age distribution of biopsied subjects (n = 55).
Histologic findings in TRB tissue samples from all the screenings (n = 55) Figure 2
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for PCa in Mexico, most of the participants did not have
antecedents of PSA screening neither prostate biopsy for can-
cer detection. This article illustrates both the ability of such
an effort to detect prostate cancer cases of whom many had
high tumor grades, as well as the surprisingly high propor-
tion (46%) of moderate to severe obstructive symptoms
among Mexican men. The U.S. Preventive Services Task Force
(USPSTF) Recommendation Statement established a thresh-
old of age at 75 for PCa screening; USPSTF recommends
against routinely providing the screening to asymptomatic
patients because found at least fair evidence that screening is
ineffective or that harms outweigh benefits [7]. In Mexico,
there is no experience about the impact of harms/benefit for
early detection screening of PCa in men older than 75 years.
In our study, a total of 98 patients were older than 75 years
and PCa was diagnosed in 3/6 subjects that underwent
biopsy (50%). This reflects the higher incidence of PCa in
older men, and accordingly, we do not oversee the benefit of
the screening for PCa in this group of men.
Only 15 cases of PCa were detected in the screenings. We
are aware that this number may be affected by the compli-
ance for biopsy in suspected subject, and additional fac-
tors, as the threshold criteria for serum PSA. Higher
Gleason scores were common among men diagnosed
with PCa and were not unsuspected, given the higher PSA
levels among these men. Nonetheless, we also detected
Gleason 7 prostate cancer in one of the subjects with a low
PSA level. The occurrence of a high grade PCa with lower
PSA levels, confirms the need for a serum marker with a
higher sensitivity to diagnose this disease. DRE proved to
be a screening test with low sensitivity (20%) and specifi-
city (82%). PSA has a respectable sensitivity (93.3%), but
a very low specificity (22.5%). These accuracy results sup-
port the plausibility of using both methods as comple-
mentary in screening efforts.
We found no important associations between known risk
factors and diagnosis of PCa. The only risk factor present
in the majority of PCa subjects in this study was age above
50 (94.73%) and the prevalence of PCa cases by age
among biopsied men older than 70 years was higher than
in the others age groups (53.33%).
Our results are dissimilar to many other screening series in
which a substantial number of cases have Gleason 6 or
lower grade disease [8,9]. In this series, the vast majority
were Gleason 7 or higher. The explanation for this phe-
nomenon is unknown. Possible reasons may include the
low frequency of screenings in the population, but may
also reflect the previously-noted lower prevalence yet
higher grade of disease among Hispanic men. Regardless,
it illustrates the importance and yet the challenge of a
screening program in Mexico: the combination of low
prevalence yet high aggressiveness would lend a greater
interest in biomarkers related to disease prognosis, as
even reasonably-good specificity rates may lead to unac-
ceptable rates of unnecessary screening and biopsy.
Some limitations for this study must be recognized. A
threshold of serum PSA of 4.0 ng/ml was established as
criterion for biopsy. Is now clear that the 2.5 ng/ml value
of serum PSA is a better threshold for PCa detection, but
this study was designed and conducted in a period in
which this PSA serum concentration was under study as a
parameter for the screenings [7,10]. The present study
does not consider the possible effect of concurrent pros-
tate infections and benign prostatic hyperplasia on the
serum PSA concentrations in the screened subjects, as has
been described [11-13]. An underestimation of cancer
diagnosis in the biopsies may be due to the use of the sex-
tant biopsy technique, the standardize method used in
screening cancer programs in Mexico. It has been showed
that increased numbers of biopsy cylinders per biopsied
patient improve the chance for detection of prostate
malignancies in suspected individuals [14-16]. Empiric
biopsies in subjects without clinical indication for pros-
tate biopsy render a better estimation of the actual PCa
prevalence in any population. We did not performed
empiric biopsies in our study. Finally, we recognize a low
compliance for the biopsy procedure (44.0%) in our
report, but it maybe reflects the historical compliance
observed in the Service of Urology of our University Hos-
pital, in which the compliance is 56.6%.
Conclusion
PSA and DRE screening tests are associated with elevated
false positive rates however the diagnostic yield of PCa is
increased using both methods as complementary in
screening efforts.
Our results reflect a low prevalence of PCa in general, but
a high occurrence of high grade lesions (Gleason ≥ 7)
among patients that resulted positive for PCa. This obser-
vation remarks the importance of the PCa screening pro-
grams in our Mexican community and the need for strict
follow-up campaigns.
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Table 3: Effectiveness of PCa diagnosis: Accuracy of PSA and 
DRE.
MEASURE PSA DRE
False Positive Rate 0.77 0.18
False Negative Rate 0.07 0.8
Sensitivity 93.30% 20%
Specificity 22.50% 82%
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